Qiagen N.V. (QGEN)
NYSE: QGEN · Real-Time Price · USD
46.64
+0.09 (0.19%)
Jun 18, 2025, 2:56 PM - Market open
Qiagen Employees
Qiagen had 5,967 employees as of December 31, 2023. The number of employees decreased by 211 or -3.42% compared to the previous year.
Employees
5,967
Change (1Y)
-211
Growth (1Y)
-3.42%
Revenue / Employee
$335,658
Profits / Employee
$15,699
Market Cap
10.10B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 5,967 | -211 | -3.42% |
Dec 31, 2022 | 6,178 | 150 | 2.49% |
Dec 31, 2021 | 6,028 | 418 | 7.45% |
Dec 31, 2020 | 5,610 | 514 | 10.09% |
Dec 31, 2019 | 5,096 | 144 | 2.91% |
Dec 31, 2018 | 4,952 | 264 | 5.63% |
Dec 31, 2017 | 4,688 | 4 | 0.09% |
Dec 31, 2016 | 4,684 | 125 | 2.74% |
Dec 31, 2015 | 4,559 | 220 | 5.07% |
Dec 31, 2014 | 4,339 | 324 | 8.07% |
Dec 31, 2013 | 4,015 | 16 | 0.40% |
Dec 31, 2012 | 3,999 | 61 | 1.55% |
Dec 31, 2011 | 3,938 | 351 | 9.79% |
Dec 31, 2010 | 3,587 | 92 | 2.63% |
Dec 31, 2009 | 3,495 | 454 | 14.93% |
Dec 31, 2008 | 3,041 | 379 | 14.24% |
Dec 31, 2007 | 2,662 | 708 | 36.23% |
Dec 31, 2006 | 1,954 | 365 | 22.97% |
Dec 31, 2005 | 1,589 | 267 | 20.20% |
Dec 31, 2004 | 1,322 | -231 | -14.87% |
Dec 31, 2003 | 1,553 | -98 | -5.94% |
Dec 31, 2002 | 1,651 | 94 | 6.04% |
Dec 31, 2001 | 1,557 | 242 | 18.40% |
Dec 31, 2000 | 1,315 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
QGEN News
- 3 days ago - QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) - Business Wire
- 12 days ago - Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors - Business Wire
- 16 days ago - QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships - Business Wire
- 16 days ago - Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma - PRNewsWire
- 26 days ago - QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions - Business Wire
- 4 weeks ago - Qiagen Beats Earnings, But Its Expensive Valuation Caps Upside Potential - Seeking Alpha
- 5 weeks ago - QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software - Business Wire
- 5 weeks ago - Qiagen N.V. (QGEN) Q1 2025 Earnings Call Transcript - Seeking Alpha